10-K: Tharimmune, Inc. Reports Annual Results for 2024, Highlights Clinical Development and Financial Position

Tharimmune, Inc. releases its 2024 annual report, detailing clinical advancements and financial results, while acknowledging substantial doubt about its ability to continue as a going concern.

Summary

• Tharimmune, Inc., a clinical-stage biotechnology company, has released its annual report on Form 10-K for the fiscal year ended December 31, 2024.
• The company is focused on developing therapeutic candidates for inflammatory and immunologic conditions.
• A patent license agreement was entered into with Avior Bio, LLC, granting rights to develop and commercialize TH104 and TH103.
• The FDA approved an IND application for TH104, a transmucosal buccal film for treating chronic pruritus.
• A Phase 2 proof-of-concept trial for TH104 is planned, along with a hepatic impairment trial.
• A patent license agreement was entered into with Intract Pharma Limited, licensing INT-023/TH023, an oral anti-TNF-alpha monoclonal antibody infliximab.
• The company is also developing early-stage pipeline candidates targeting immuno-oncology targets such as HER2, HER3, PD-1, and VEGF.
• The company reported a net loss of $12.2 million for the year ended December 31, 2024, and an accumulated deficit of $36.9 million.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• The company will require substantial additional capital to finance its operations.
• The company is pursuing a 505(b)(2) approval pathway for TH104.
• The company is planning a hepatic impairment study in 2025 to fully evaluate the pharmacokinetic profile and safety in certain stages of liver impairment.
• The company is planning a Phase 2 trial with TH104 in moderate-to-severe chronic pruritus in PBC patients in early 2025.
• The company is pursuing the CMC plan in 2025 for TH023 and intends to begin planning a human phase 1 trial to be conducted outside the United States as an initial proof-of-concept.
• The company is planning to submit INDs to the FDA for HS3215 and HS1940 in 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical pipeline, the financial situation and going concern warning weigh heavily on the overall sentiment.

Positives

• The FDA approved an IND application for TH104, a transmucosal buccal film for treating chronic pruritus.
• A Phase 2 proof-of-concept trial for TH104 is planned, along with a hepatic impairment trial.
• A patent license agreement was entered into with Intract Pharma Limited, licensing INT-023/TH023, an oral anti-TNF-alpha monoclonal antibody infliximab.
• The company is also developing early-stage pipeline candidates targeting immuno-oncology targets such as HER2, HER3, PD-1, and VEGF.
• The company is pursuing a 505(b)(2) approval pathway for TH104.
• The company is planning a hepatic impairment study in 2025 to fully evaluate the pharmacokinetic profile and safety in certain stages of liver impairment.
• The company is planning a Phase 2 trial with TH104 in moderate-to-severe chronic pruritus in PBC patients in early 2025.

Negatives

• The company reported a net loss of $12.2 million for the year ended December 31, 2024, and an accumulated deficit of $36.9 million.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• The company will require substantial additional capital to finance its operations.

Risks

• The company has a limited operating history, which may make it difficult to evaluate its current business and predict its future performance.
• The company has incurred significant losses since inception, and expects to incur losses in the future.
• The company will require substantial additional funding, and may be forced to curtail, delay, or discontinue development programs if unable to raise capital.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's business depends on the successful clinical development, regulatory approval, and commercialization of its therapeutic compounds.
• There are substantial risks inherent in drug development, and the company may not be able to successfully develop its product candidates.
• The company depends on license agreements with partners, and termination of these rights could materially harm its business.
• The company is substantially dependent on the success of its product candidates.
• Any delays in the commencement or completion of clinical trials could result in increased costs and delay or limit the ability to generate revenue.
• Adverse side effects or other safety risks associated with the company's drug candidates could delay or preclude approval, cause suspension of clinical trials, or limit the commercial profile of an approved label.
• The company relies on third parties to manufacture its product candidates and conduct pre-clinical studies and clinical trials.
• The company currently depends on sole source suppliers and manufacturers for certain ingredients.
• The company may not be successful in commercializing one or more of its drug candidates.
• The development and commercialization of pharmaceutical products are subject to extensive regulation.
• The company's inability to protect its intellectual property and proprietary rights may have a material adverse effect on its business.
• The company may encounter difficulties in managing its growth.
• The company's employees, independent contractors, consultants, commercial partners, collaborators, and vendors may engage in misconduct or other improper activities.
• Significant disruptions of information technology systems or breaches of data security could adversely affect the company's business.
• The company is currently listed on The Nasdaq Capital Market, and if it is unable to maintain listing, its stock price could be adversely affected.

Future Outlook

The company plans to advance TH104 through clinical trials, develop TH023, and create a preclinical and clinical path forward for HS1940. The company also intends to hasten the discovery and development of next-generation multi-specific antibodies and pursue strategic collaboration opportunities.

Industry Context

The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products and intellectual property. Tharimmune faces competition from major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions both in the United States and internationally.

Comparison to Industry Standards

• The document mentions several competitors for TH104, including Mirum Pharma, Ipsen Pharma, Cara Therapeutics, Moonlake Therapeutics, Apogee Therapeutics, and Regeneron.
• For the early-stage pipeline, competitors include Bayer AG, Moderna Inc., Roche/Genentech, Daiichi Sankyo/Astra Zeneca, Merck, Bristol-Myers Squibb and Takeda Pharmaceutical Company.
• The document references Roche/Genentech's HER2 targeted therapies with worldwide sales of over $8 billion in 2022, and AstraZeneca's ENHERTU with more than $500 million in worldwide sales in the first half of 2023 alone, indicating the potential market size for HER2 targeted therapies.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment due to the company's financial condition.
• Employees face uncertainty regarding job security due to the company's going concern warning.
• Patients may benefit from the development of new therapies, but face uncertainty regarding the availability and affordability of these therapies.
• Suppliers and creditors face the risk of non-payment due to the company's financial condition.

Next Steps

• Conduct a hepatic impairment study in 2025 to fully evaluate the pharmacokinetic profile and safety in certain stages of liver impairment.
• Plan a Phase 2 trial with TH104 in moderate-to-severe chronic pruritus in PBC patients in early 2025.
• Pursue the CMC plan in 2025 for TH023 and intends to begin planning a human phase 1 trial to be conducted outside the United States as an initial proof-of-concept.
• Submit INDs to the FDA for HS3215 and HS1940 in 2025.

Key Dates

Keywords

TH104, TH023, HS1940, HS3215, Clinical Trials, Biotechnology, Pharmaceutical, Immunology, Inflammation, Oncology, FDA, IND, PBC, Pruritus, License Agreement, Capital, Funding